Department of Surgery, The University of Melbourne, Melbourne, VIC, Australia.
Department of Surgery, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Eur J Cardiothorac Surg. 2023 Jun 1;63(6). doi: 10.1093/ejcts/ezad091.
Diabetics may have diminished survival after coronary artery bypass grafting even with multiple arterial revascularization. We compared multi-arterial versus single-arterial grafting (SAG) survival in diabetic and non-diabetic patients undergoing primary isolated bypass surgery.
This is a retrospective analysis of the Australian and New Zealand Society of Cardiac-Thoracic Surgical Database from June 2001 to January 2020. Patients were classified as having either single or multiple arterial grafting irrespective of the number of venous grafts. The end points were long-term all-cause mortality and 30-day clinical outcomes, which was compared in 1:1 propensity score-matched patients. Cox regression model was used to assess interactions between diabetes and the treatment effect of multi-arterial grafting, reported as hazard ratios (HRs) and confidence intervals (CIs). Short-term outcomes were compared with McNemar's paired t-test.
From 69 624 patients, matching generated 17 474 non-diabetic and 10 989 diabetic patient pairs. At a median [interquartile range] of 5.9 [3.2-9.6] years postoperative, mortality was significantly lower after multi-arterial grafting for both diabetic (HR, 0.83; 95% CI, 0.76-0.90, P < 0.001) and non-diabetic (HR, 0.88; 95% CI, 0.82-0.95; P < 0.001) cohorts than SAG. The incidence of 30-day myocardial infarction was significantly higher in single than multiple arterial grafting for both cohorts (diabetic, P = 0.029; non-diabetic, P < 0.001). The interaction analysis suggested an insignificant effect of diabetes (P = 0.55) on the observed survival advantage. Further stratification by diabetic management generated consistent results.
Multi-arterial grafting was associated with improved overall survival compared to SAG for both non-diabetic and diabetic patients.
即使进行了多支动脉血管重建,糖尿病患者在冠状动脉旁路移植术后的生存率可能仍会降低。我们比较了糖尿病患者和非糖尿病患者在接受单纯旁路手术时,多支动脉血管与单支动脉血管(SAG)重建的生存情况。
这是对澳大利亚和新西兰心胸外科协会数据库 2001 年 6 月至 2020 年 1 月的一项回顾性分析。患者被分为接受单支或多支动脉血管移植的患者,无论静脉移植的数量如何。主要终点为长期全因死亡率和 30 天临床结局,在 1:1 倾向评分匹配的患者中进行比较。Cox 回归模型用于评估糖尿病与多支动脉血管移植治疗效果之间的交互作用,以风险比(HR)和置信区间(CI)表示。短期结局采用 McNemar 配对 t 检验进行比较。
在 69624 例患者中,匹配生成了 17474 例非糖尿病患者和 10989 例糖尿病患者。术后中位数(四分位距)为 5.9(3.2-9.6)年,多支动脉血管移植后糖尿病患者(HR,0.83;95%CI,0.76-0.90,P<0.001)和非糖尿病患者(HR,0.88;95%CI,0.82-0.95;P<0.001)的死亡率均显著低于 SAG。两组患者 SAG 组 30 天心肌梗死发生率均显著高于多支动脉血管移植组(糖尿病患者,P=0.029;非糖尿病患者,P<0.001)。交互作用分析表明,糖尿病的影响不显著(P=0.55)。进一步按糖尿病管理分层,结果一致。
与 SAG 相比,多支动脉血管移植可改善非糖尿病患者和糖尿病患者的整体生存率。